高科桥(09963)发布公告，于2025年12月17日，本公司与联席配售代理订立配售协议，据此，本公司有 条件同意通过联席配售代理按竭诚尽力基准以每股配售股份0.476港元的配售价向不少于6名承配人(彼 等及彼等的实益拥有人须为独立第三方)配售最多5200万股配售股份。 假设全部配售股份获悉数配售，则配售事项所得款项总额预期约为2480万港元，而所得款项净额(经扣 除配售佣金及其他配售开支)将约为2440万港元。按此计算，每股配售股份的净价将约为0.469港元。本 公司拟将(i)32.8%的所得款项净额用于偿还银行及其他借贷及(ii)67.2%的所得款项净额用于一般营运资 金。 配售股份相当于于本公布日期已发行股份总数约20.00%，及配售事项完成后经扩大已发行股份总数约 16.67%(假设由本公佈日期至配售事项完成期间，除本公司发行配售股份外，已发行股份总数并无变 动)。配售价较于2025年12月17日在联交所所报每股股份0.54港元的收市价折让约11.85%。 ...

格隆汇12月17日丨高科桥(09963.HK)公告，于2025年12月17日，公司与联席配售代理订立配售协议，据 此，公司有条件同意通过联席配售代理按竭诚尽力基准以每股配售股份0.476港元的配售价向不少于六 (6)名承配人(彼等及彼等的实益拥有人须为独立第三方)配售最多5200万股配售股份。 配售股份相当于于本公布日期已发行股份总数约20.00%，及配售事项完成后经扩大已发行股份总数约 16.67%(假设由本公布日期至配售事项完成期间，除公司发行配售股份外，已发行股份总数并无变动)。 配售价较于配售协议日期在联交所所报每股股份0.54港元收市价折让约11.85%；配售事项所得款项总额 预期约为2480万港元，而所得款项净额(经扣除配售佣金及其他配售开支)将约为2440万港元。按此计 算，每股配售股份的净价将约为0.469港元。 ...

Group 1 - The company Eternity Strategy (00764) announced a plan to place a maximum of 20 million shares, which represents approximately 4.96% of the enlarged issued share capital after the placement [1] - The placement price is set at HKD 1.00 per share, and if the maximum number of shares is placed, the total proceeds from the placement will amount to HKD 20 million [1] - The net proceeds from the placement are expected to be approximately HKD 19.6 million, which the company intends to use for repaying group debt and general working capital [1]

智通财经APP讯，永恒策略(00764)发布公告，于2025年12月17日，公司拟配售最多2000万股，相当于公 司经配发及发行配售股份扩大后的已发行股本约4.96%。配售价为每股配售股份1.00港元。假设根据配 售协议配售配售股份最高数目，配售事项所得款项总额将为2000万港元，而所得款项净额将约为1960万 港元。公司拟将所得款项净额用于偿还集团债务及一般营运资金。 ...

假设根据配售协议配售配售股份最高数目，配售事项所得款项总额将为2000万港元，而所得款项净额将 约为1960万港元(经扣除配售事项之佣金及其他开支)。公司拟将所得款项净额用于偿还集团债务及一般 营运资金。 格隆汇12月17日丨永恒策略(00764.HK)公告，于2025年12月17日，公司与配售代理订立配售协议，据 此，公司有条件同意透过配售代理按竭尽所能基准按配售价为每股配售股份1.00港元向不少于六名承配 人配售最多2000万股配售股份，而彼等及彼等之最终实益拥有人均为独立第三方。 ...

Core Viewpoint - The company, Gao Shan Enterprises (00616), has announced a conditional placement of up to 67 million shares at a price of HKD 0.30 per share, which represents a discount to the market price on the date of the agreement [1][2]. Group 1: Share Placement Details - The maximum number of shares to be placed represents approximately 4.03% of the company's issued share capital as of the announcement date, and about 3.87% assuming all placement shares are issued [1]. - The placement price of HKD 0.30 per share is approximately 10.45% lower than the closing price of HKD 0.335 on December 16, 2025, and about 10.98% lower than the average closing price of HKD 0.337 over the preceding five trading days [1]. - The expected total gross proceeds from the placement, after deducting commissions and related costs, are approximately HKD 20.10 million, with a net amount of about HKD 19.89 million [1]. Group 2: Use of Proceeds - The net proceeds from the placement, estimated at approximately HKD 0.297 per share, will be used to cover additional construction costs for the Fenghua project located at 646, 648, and 648A Castle Peak Road, Kowloon [2]. - The total area of the site for the Fenghua project is approximately 9,206 square feet, and the development plan has been adjusted to convert it into student dormitories due to current market conditions [2].

公司将自配售事项收取的所得款项总额及所得款项净额估计分别约为2.014亿港元及1.977亿港元。配售 事项的所得款项净额将按以下方式及比例动用：90%用于偿还银行贷款，本金总额约为5.31亿港元，当 中涉及53笔银行贷款，每笔贷款金额介乎约5.9万港元至约1.28亿港元，到期日范围介乎2025年12月至 2026年9月期间；及10%用于集团的一般营运资金，包括集团的租金成本、员工开支、专业费用及其他 行政开支。 配售股份相当于公司于本公告日期已发行股本总数约3.83%。配售价每股H股22.68港元，较H股于12月 15日(即最后交易日及配售价厘定日期)在联交所所报的收市价每股26.68港元折让约14.99%。配售股份将 根据一般授权配发及发行。 格隆汇12月16日丨亿华通(02402.HK)发布公告，2025年12月16日，公司与配售代理(即国泰君安国际)订 立配售协议，据此，配售代理已有条件同意根据配售协议所载条款并在其条件规限下，按尽力基准促使 不少于六名承配人按配售价认购最多888万股新H股。 ...

Group 1 - The core point of the article is that Dingyi Group Investment has provided supplementary disclosure regarding the use of proceeds from a placement completed between July and August 2024, raising approximately HKD 53.10 million [1] - The company placed 115,000,000 ordinary shares at a price of HKD 0.47 per share [1] - Of the net proceeds, HKD 31.86 million is allocated for investment opportunities, while HKD 21.24 million is designated for general working capital [1] - As of March 31, 2025, and the announcement date, the unutilized balance of proceeds is zero [1]

Group 1 - The company has entered into a placement agreement with joint placement agents to issue 5.136 million shares at a price of HKD 58.41 per share, targeting at least six subscribers [2] - The placement shares represent approximately 1.84% of the issued H shares and about 1.33% of the total issued shares as of the announcement date, and will account for approximately 1.81% of H shares and 1.31% of total shares post-issuance [2] Group 2 - The placement price of HKD 58.41 per share reflects a 10% discount compared to the closing price of HKD 64.90 per share on December 12, 2025 [3] - The estimated net proceeds from the placement are approximately HKD 296 million, with around 40% allocated for building a next-generation intelligent R&D and data platform, 28% for loan repayment and strengthening capital structure, 12% for ongoing and planned R&D of PB-2301 and PB-2309, 10% for establishing a subsidiary in Hong Kong and accelerating overseas business expansion, and 10% for general corporate purposes and working capital [3]

假设所有配售股份获悉数配售，配售的估计所得款项总额及所得款项净额(经扣除本公司将承担的相关 成本及开支后)将分别为约3亿港元及约2.96亿港元。其中：1.约40%，构建新一代智能化研发与数据平 台;2.约28%，偿还贷款及强化本公司资本结构;3.约12%，持续及计划研发PB-2301及PB-2309;4.约10%， 设立香港附属公司及加快本集团海外业务布局;5.约10%，一般公司用途及营运资金。 假设于本公告日期至完成日期期间本公司的已发行股本并无变动，513.6万股配售股份之总数相当于： (i)本公告日期已发行H股的约1.84%及已发行股份总数的约1.33%;及(ii)经配发及发行配售股份扩大的H 股的约1.81%及股份总数的约1.31%。配售价为每股配售股份58.41港元，较H股于2025年12月12日(香港 时间)(即配售协议日期)在联交所所报的收市价每股64.90港元折让10%。 派格生物医药-B(02565)发布公告，于2025年12月12日(交易时段后)，本公司与联席配售代理订立配售协 议，据此，本公司已有条件同意透过联席配售代理按尽力基准以每股配售股份58.41港元的价格向不少 于六名承配人配售 ...